Sheba Medical Center
| Israel | Turkey | Austria | |
| Immunotherapy | from $2,400 | from $2,200 | from $30,000 |
| Immunotherapy for prostate cancer | from $2,250 | from $12,000 | from $30,000 |
| CAR T-cell therapy | from $72,000 | from $150,000 | from $350,000 |
| Immunotherapy with Keytruda (Pembolizumab) | from $9,800 | from $3,300 | from $15,000 |
| Sarcoma Immunotherapy | - | from $18,000 | from $60,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Immunotherapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy journey.
Bookimed, a leading global medical tourism platform, is committed to helping clients looking for Immunotherapy in Israel by offering expert assistance and trustworthy medical solutions for every situation. Smart automatic ranking system is used to compose transparent clinic listings, meticulously maintained by a data scientist using AI for accuracy. The platform guarantees authenticity by publishing reviews from real patients after their treatments. Bookimed offers comprehensive medical solutions, with updates from clinics to ensure trustworthiness. The content about Immunotherapy in Israel, crafted by experienced medical authors and reviewed by specialists, adheres to Bookimed"s Editorial Guidelines, reflecting the platform"s commitment to delivering high-quality and clear health information. For more details or inquiries, feel free to contact us at marketing@bookimed.com or learn more about us and our mission here.
Prof. Amit Tirosh leads the Neuroendocrine Tumors Service at Sheba Medical Center, specializing in complex hereditary syndromes.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Prof. Ben Boursi leads groundbreaking research on microbiome's role in cancer therapy – his work is published in Science and featured at ASCO.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.
Written by Kateryna Zamkovska
Written by Kateryna Zamkovska
Written by Kateryna Zamkovska